Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Short bowel syndrome with intestinal failure Indication Strategy Report 2026: GLP-2, Trials and Deals
3 August 2026
2026 Short bowel syndrome with intestinal failure indication strategy covering epidemiology, GLP-2 biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Gastroparesis diabetic Indication Strategy Report 2026: GHRL, Trials and Deals
3 August 2026
2026 Gastroparesis diabetic indication strategy covering epidemiology, GHRL biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Intestinal lymphangiectasia Indication Strategy Report 2026: VEGFR3, Trials and Deals
3 August 2026
2026 Intestinal lymphangiectasia indication strategy covering epidemiology, VEGFR3 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Collagenous colitis Indication Strategy Report 2026: JAK, Trials and Deals
3 August 2026
2026 Collagenous colitis indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Lymphocytic colitis Indication Strategy Report 2026: JAK, Trials and Deals
3 August 2026
2026 Lymphocytic colitis indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Collagenous gastritis Indication Strategy Report 2026: JAK, Trials and Deals
3 August 2026
2026 Collagenous gastritis indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Eosinophilic gastroenteritis Indication Strategy Report 2026: IL-5, Trials and Deals
3 August 2026
2026 Eosinophilic gastroenteritis indication strategy covering epidemiology, IL-5 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Gastric antral vascular ectasia Indication Strategy Report 2026: VEGF, Trials and Deals
3 August 2026
2026 Gastric antral vascular ectasia indication strategy covering epidemiology, VEGF biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Portal hypertensive gastropathy Indication Strategy Report 2026: VEGF, Trials and Deals
3 August 2026
2026 Portal hypertensive gastropathy indication strategy covering epidemiology, VEGF biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Lean metabolic dysfunction-associated steatotic liver disease Indication Strategy Report 2026: FGF21, Trials and Deals
3 August 2026
2026 Lean metabolic dysfunction-associated steatotic liver disease indication strategy covering epidemiology, FGF21 biology, active trials, transactions, unmet…
Latest Hotspot
8 min read
Metabolic dysfunction-associated steatohepatitis Indication Strategy Report 2026: THR-beta, Trials and Deals
3 August 2026
2026 Metabolic dysfunction-associated steatohepatitis indication strategy covering epidemiology, THR-beta biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Alcohol-associated cirrhosis Indication Strategy Report 2026: TGF-beta, Trials and Deals
3 August 2026
2026 Alcohol-associated cirrhosis indication strategy covering epidemiology, TGF-beta biology, active trials, transactions, unmet need, competition and market…